Aminosalicylates

详细信息    查看全文

• 作者：Christoph  ; Campregher PhD ; Postdoctoral Scientist ; Christoph  ; Gasche MD  ; ;   ; ^{christoph.gasche@meduniwien.ac.at} ; Professor in Gastroenterology ; Head of Christian Doppler Laboratory for Molecular Cancer Chemoprevention
• 关键词：Aminosalicylates ; Inflammatory bowel disease ; Ulcerative colitis ; Colorectal cancer
• 刊名：Best Practice Research Clinical Gastroenterology
• 出版年：2011
• 出版时间：August-October 2011
• 年：2011
• 卷：25
• 期：4-5
• 页码：535-546
• 全文大小：545 K

文摘

Aminosalicylates are the most common drugs for the primary treatment of inflammatory bowel disease. Various pro-drugs and formulations were developed in order to improve pharmacological profiles, optimize bioavailability and to gain highest efficacy in the treatment of ulcerative colitis (UC) and Crohn¡¯s disease. In vitro studies have greatly contributed to the understanding of the molecular actions in?vivo and clinical studies have proven aminosalicylates to be effective and safe. This review summarizes the current knowledge on the molecular, pharmacological and clinical properties of aminosalicylates with respect to chemoprevention for UC-associated colorectal cancer.